See more : DICE Therapeutics, Inc. (DICE) Income Statement Analysis – Financial Results
Complete financial analysis of Biostar Pharmaceuticals, Inc. (BSPM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Biostar Pharmaceuticals, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Welby Inc. (4438.T) Income Statement Analysis – Financial Results
- Satori Electric Co., Ltd. (7420.T) Income Statement Analysis – Financial Results
- Agronomics Limited (ANIC.L) Income Statement Analysis – Financial Results
- AGC Inc. (5201.T) Income Statement Analysis – Financial Results
- Siemens Healthineers AG (SHL.DE) Income Statement Analysis – Financial Results
Biostar Pharmaceuticals, Inc. (BSPM)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://biostarpharmaceuticals.com
About Biostar Pharmaceuticals, Inc.
Biostar Pharmaceuticals, Inc. develops, manufactures, and markets over-the-counter (OTC) and prescription pharmaceutical products for various diseases and conditions in the People's Republic of China. The company principally offers Xin Ao Xing Oleanolic Acid capsule, an OTC medicine for chronic hepatitis B. It also provides 12 other OTC products and 17 prescription-based pharmaceuticals. The company's OTC products also comprise Ganwang compound paracetamol and amantadine hydrochloride capsule for the relief of common cold, runny nose, sore throat, headache, and fever; Tianqi Dysmenorrhea capsule, a traditional Chinese medicine used for pain and other symptoms associated with menstruation; Deafness Tongqiao pills for hepatobiliary Huosheng, head swelling, deafness and tinnitus, ear pus, dry stool, and urine-yellow; Wenweishu capsules for the treatment of chronic gastritis and pain of epigastric cold; Zhitongtougu ointment for treating joint pain, swelling, tenderness, or dysfunction; and Chuzhang Zehaifu tablets for cataract. Its prescription pharmaceutical products include Danshen granules; Taohuasan pediatric medicines; Jingang tablets; Danxiang Rhinitis tablets; Yanlixiao capsules; Piracetam tablets; Huangyangning tablets; Hyperthyroidism capsules; Fosfomycin Calcium capsules; Qianlietong capsules; Yituo Erythromycin particles; Danshen tablets; Muxiang Shunqi pills; Sifangwei capsules; and Aspirin Enteric-coated tablets. The company also operates a Website that serves as Internet-based China Hepatitis Internet hospital, which offers HBV patients with information on HBV and treatment options, as well as methods to purchase HBV medicines. Biostar Pharmaceuticals, Inc. sells its products through distributors and a network of sales people in approximately 28 provinces. The company was incorporated in 2007 and is headquartered in Xianyang, the People's Republic of China.
| Metric | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.38M | 27.13M | 61.42M | 52.73M | 49.32M | 91.97M | 80.21M | 53.32M | 33.91M | 15.89M |
| Cost of Revenue | 1.47M | 16.03M | 31.14M | 27.05M | 19.47M | 27.58M | 20.08M | 14.31M | 14.06M | 5.22M |
| Gross Profit | 915.17K | 11.10M | 30.28M | 25.68M | 29.85M | 64.39M | 60.14M | 39.00M | 19.85M | 10.66M |
| Gross Profit Ratio | 38.38% | 40.93% | 49.30% | 48.71% | 60.53% | 70.01% | 74.97% | 73.15% | 58.54% | 67.12% |
| Research & Development | 1.14M | 4.02M | 2.77M | 3.23M | 4.48M | 2.32M | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 2.43M | 4.65M | 7.72M | 6.09M | 5.95M | 5.68M | 4.21M | 23.90M | 0.00 | 0.00 |
| Selling & Marketing | 1.17M | 8.64M | 18.49M | 16.58M | 27.89M | 38.23M | 32.31M | 0.00 | 0.00 | 0.00 |
| SG&A | 3.60M | 13.29M | 26.21M | 22.67M | 33.84M | 43.90M | 36.53M | 23.90M | 12.09M | 5.82M |
| Other Expenses | -265.49K | 4.67M | 67.00 | -1.29M | 3.67M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 4.48M | 21.98M | 28.97M | 24.60M | 41.99M | 46.23M | 36.53M | 23.90M | 12.09M | 5.82M |
| Cost & Expenses | 5.95M | 38.00M | 60.11M | 51.65M | 61.46M | 73.81M | 56.60M | 38.22M | 26.15M | 11.04M |
| Interest Income | 1.17K | 8.90K | 1.33M | 1.34M | 296.15K | 430.02K | 34.02K | 2.90K | 2.91K | 3.49K |
| Interest Expense | 206.20K | 283.60K | 154.55K | 367.49K | 84.39K | 41.94K | 0.00 | 0.00 | 40.62K | 60.29K |
| Depreciation & Amortization | 1.14M | 2.24M | 3.09M | 2.79M | 2.12M | 885.12K | 620.02K | 607.65K | 645.85K | 589.87K |
| EBITDA | -1.70M | -21.19M | 4.39M | 3.54M | -21.49M | 18.99M | 24.07M | 15.71M | 8.41M | 5.44M |
| EBITDA Ratio | -80.68% | -31.80% | 9.32% | 9.88% | -20.31% | 21.18% | 30.44% | 29.47% | 24.80% | 34.24% |
| Operating Income | -3.56M | -10.87M | 2.64M | 2.43M | -12.14M | 18.16M | 23.61M | 15.10M | 7.76M | 4.85M |
| Operating Income Ratio | -149.48% | -40.07% | 4.29% | 4.60% | -24.62% | 19.75% | 29.43% | 28.32% | 22.89% | 30.50% |
| Total Other Income/Expenses | 518.93K | -35.15K | 2.85M | 230.86K | -1.39M | -92.90K | -155.58K | -352.08K | -37.70K | -60.80K |
| Income Before Tax | -3.05M | -23.79M | 1.53M | 2.66M | -21.57M | 18.07M | 23.45M | 14.75M | 7.72M | 4.78M |
| Income Before Tax Ratio | -127.71% | -87.70% | 2.50% | 5.04% | -43.74% | 19.64% | 29.24% | 27.66% | 22.78% | 30.12% |
| Income Tax Expense | 2.65M | 1.32M | -3.31M | 1.85M | -1.58M | 5.89M | 6.07M | 4.25M | 1.03M | 821.44K |
| Net Income | -5.70M | -25.11M | 4.85M | 809.05K | -20.00M | 12.17M | 17.38M | 10.50M | 6.69M | 3.96M |
| Net Income Ratio | -238.98% | -92.57% | 7.89% | 1.53% | -40.55% | 13.24% | 21.67% | 19.69% | 19.73% | 24.95% |
| EPS | -2.48 | -11.36 | 2.30 | 0.49 | -14.63 | 9.17 | 13.86 | 7.14 | 4.83 | 4.20 |
| EPS Diluted | -2.48 | -11.36 | 2.30 | 0.49 | -14.63 | 9.17 | 13.23 | 6.72 | 4.62 | 3.99 |
| Weighted Avg Shares Out | 2.30M | 2.21M | 2.07M | 1.64M | 1.37M | 1.33M | 1.26M | 1.11M | 1.07M | 962.86K |
| Weighted Avg Shares Out (Dil) | 2.30M | 2.21M | 2.07M | 1.64M | 1.37M | 1.33M | 1.31M | 1.16M | 1.11M | 993.25K |
Source: https://incomestatements.info
Category: Stock Reports